Friday, March 17, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Defense + Military

DARPA Seeks Proposals for In Vivo Nanotherapeutics

by Global Biodefense Staff
June 12, 2012

The Defense Advanced Research Project Agency (DARPA) is seeking proposals for innovative technology in support of the In vivo Nanoplatforms for Therapeutics (IVN:Tx) initiative. The effort was announced in a Broad Agency Announcement (BAA) released this week.

The overall program objective is to develop radically new classes of adaptable, biocompatible nanotherapeutic platforms that can be programmed “on-the-fly” to treat military-relevant diseases.  The IVN:Tx thrust is for development of new methods to increase nanotherapeutic safety that minimizes the dose required for clinically relevant efficacy and limits immunogenicity.

IVN:Tx also seeks to develop new methods to increase nanotherapeutic effectiveness by targeting delivery to specific tissues or uptake by cells of interest, increasing bioavailability, knocking down medically relevant molecular targets, and increasing resistance to degradation. The solicitation specifically mentions that “successful nanotherapeutic platforms should enable treatment of military-relevant diseases such as infections caused by multi-drug resistant organisms and conditions due to traumatic brain injury.”

Under a separate BAA, DARPA solicited proposals to develop the nanoscale systems necessary for in vivo sensing and physiologic monitoring of warfighters as components of the In vivo Nanoplatforms for Diagnostics (IVN:Dx) thrust of the IVN program. This companion solicitation for the In vivo Nanoplatforms for Therapeutics (IVN:Tx) thrust seeks proposals describing novel nanotherapeutics with tailored sequence, specificity, and functionality to address the therapeutics objective of the program.

Together these BAAs work to will enable a versatile and rapidly adaptable system to provide medical and operational support to the warfighter in any location. DARPA encourages the development of standalone diagnostic and therapeutic technologies within each thrust in order to optimize the technologies, capabilities, and applications developed within the IVN program.  Proposals to develop small molecule therapeutics for treatment of a specific disease are not being sought under this BAA.

Full details are available under Solicitation Number: DARPA-BAA-12-34. Proposal abstracts are due July 18, 2012. The full proposal response deadline is September 18, 2012.

Tags: BAADARPANanotech

Related Posts

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy